Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Palma – page 29

371 clinical trials in Palma, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Palma at a glance
371
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

371 trials in Palma

Open in trial search

Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aclidinium Bromide
  • Sponsor:Fundacio Privada Mon Clinic Barcelona

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

End stage renal disease+1

Not recruiting

Study Comparing Rifampicin, Isoniazid, and Rifapentine Regimens for Treating Latent Tuberculosis in Patients with End-Stage Kidney Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Isoniazid
  • Sponsor:Bellvitge University Hospital

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Study Comparing Aficamten and Metoprolol for Adults with Symptomatic Hypertrophic Cardiomyopathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Roche Farma S.A.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Solti Group

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Palma

What the registry says about research in the country

01 Neoplasms

The cancer research activity in Palma De Mallorca focuses on improving treatment options for multiple myeloma, relapsed refractory multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and advanced non-small cell lung cancer. These studies are designed to assess whether newer therapies can improve disease control and patient outcomes.

  • Relapsed and refractory multiple myeloma
  • Newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
  • Advanced non-small cell lung cancer with KRAS G12C mutation
  • Evaluating treatment effectiveness and disease response

Across these trials, researchers are comparing innovative approaches with existing care to better understand how to extend survival and deepen responses.

02 Cardiovascular Diseases

Clinical trial work in cardiovascular diseases is centered on primary prevention of atherosclerotic cardiovascular disease. The main goal is to see whether new preventive strategies can lower the risk of serious heart and vascular events in people at elevated risk.

  • Atherosclerotic cardiovascular disease prevention
  • Reducing major adverse cardiovascular events
  • Testing preventive treatment effectiveness

These studies aim to strengthen early prevention and support better long-term cardiovascular health.

03 Hemic and Lymphatic Diseases

This research area includes studies in hematologic cancers such as multiple myeloma, relapsed refractory multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome. The focus is on testing therapies that may improve control of blood-related malignancies and deepen treatment responses.

  • Multiple myeloma and relapsed refractory disease
  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Assessing therapeutic benefit in blood cancers

Investigators are working to refine treatment strategies for patients with difficult-to-treat hematologic conditions.

04 Nervous System Diseases

Trials in nervous system diseases are exploring better ways to prevent and ease chronic postsurgical pain after inguinal hernia repair. The aim is to reduce the chance that short-term surgical pain becomes a lasting problem.

  • Chronic postsurgical pain
  • Pain after inguinal hernia repair
  • Improving postoperative symptom control

These studies focus on making recovery more comfortable and helping patients return to normal activity more smoothly.

05 Stomatognathic Diseases

Research in stomatognathic diseases is examining ways to prevent clinically relevant oral bleeding after tooth extraction in patients using direct oral anticoagulants or vitamin K antagonists. The purpose is to improve safety in everyday dental care for people on blood-thinning treatment.

  • Oral bleeding after tooth extraction
  • Patients treated with anticoagulants
  • Preventing postoperative hematomas

These studies aim to support safer dental procedures without compromising cardiovascular protection.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.